论文部分内容阅读
目的观察贝那普利和卡维地洛联合应用治疗慢性心力衰竭(CHF)的临床疗效。方法将86例慢性心力衰竭(CHF)患者随机分成贝那普利和卡维地洛联合治疗组(简称治疗组,46例)及贝那普利组(简称对照组,40例)。对照组用药除了无卡维地洛外余用药同治疗组。观察随访12个月。观察指标包括血压(SBP,DBP)、心率(HR)、左室舒张末内径(LVEDd)、每博输出量(SV)、左心室射血分数(LVEF)的变化情况。结果治疗组和对照组的总有效率分别为93.5%和80.0%,治疗组和对照组治疗12个月后SBP、DBP、HR、LVEDd均显著下降,SV、LVEF显著提高,且治疗组上述指标改善尤为显著。结论贝那普利联合卡维地洛治疗慢性心力衰竭安全有效,可显著提高对CHF患者的临床疗效。
Objective To observe the clinical efficacy of benazepril combined with carvedilol in the treatment of chronic heart failure (CHF). Methods Eighty-six patients with chronic heart failure (CHF) were randomly divided into benazepril combined with carvedilol group (n = 46) and benazepril group (n = 40). In addition to the control group medication without carvedilol treatment with the same group. Follow-up observation for 12 months. The observation included the changes of SBP, DBP, HR, LVEDd, SV, LVEF. Results The total effective rates of the treatment group and the control group were 93.5% and 80.0% respectively. The SBP, DBP, HR, LVEDd, SV and LVEF were significantly decreased in the treatment group and the control group after 12 months of treatment, and the above indexes The improvement is especially noticeable. Conclusion The combination of benazepril and carvedilol in the treatment of chronic heart failure is safe and effective, which can significantly improve the clinical efficacy of CHF.